Gut microbiota is instrumental in the microbial and metabolic network of pregnant women, and is potentially related with gestational diabetes. Perinatal probiotic intervention contributes to improved glucose regulation during pregnancy. Our randomized, double-centered, placebo-controlled study is planned to recruit 334 pregnant women who is in high risk for gestational diabetes. They will be assumed randomly probiotic powder per day or placebo from 12-16th gestational weeks until Oral Glucose Tolerance Test (OGTT) at 24-28th gestational weeks. Perinatal outcomes about neonatal weight will be registered.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
334
Probiotics powder including: Resistant dextrin, inulin, oligosaccharide, erythritol, Lactobacillus plantarum VB165, Bifidobacterium lactis VB301, Lactobacillus rhamnosus VB255, acerola cherry powder, citric acid
placebo with similar appearance and smell but not containing probiotics
Women's Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
RECRUITINGthe incidence of gestational diabetes
The number of cases and incidence of gestational diabetes according to OGTT
Time frame: 24-28th weeks gestation
The incidence of macrosomia
macrosomia refers to a newborn weighs more than 4 kg)
Time frame: Delivery
Weight gain during pregnancy (kg)
Weight gain during pregnancy (kg) = Maternal weight at delivery - weight pre-pregnancy
Time frame: Delivery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.